Citations

Mayo Clinic

Showing 10 of 108572 citations.

Early Cholecystectomy in Patients with Sickle Cell Disease with Uncomplicated Cholelithiasis Is Associated with Better Outcomes
Cornwell, Edward E., Fullum, Terrence M., Chu, Quyen D. , Ayad, Marco H, Li, Sandy , Williams, Mallory , Kearse, LaDonna , Zeineddin, Ahmad

Journal of the American College of Surgeons | January 9, 2024 | Volume: 238 | Issue: 4 | Pages: 543-550

10.1097/xcs.0000000000000949 | PMID 38193560 Get It

BACKGROUND: Up to 85% of patients with sickle cell disease (SCD) will develop gallstones by their third decade. Cholecystectomy is the most commonly performed procedure in these patients. Cholecystectomy is recommended for patients with SCD with symptomatic cholelithiasis and leads to lower morbidity. No contemporary large studies have evaluated this recommendation or associated clinical outcomes. This study evaluates clinical outcomes after cholecystectomy in patients with SCD and cholelithiasis with specific advanced clinical presentations. STUDY DESIGN: The Nationwide Inpatient Sample was queried for patients with SCD and gallbladder disease between 2006 and 2015. Patients were divided into groups based on their disease presentation, including uncomplicated cholelithiasis, acute and chronic cholecystitis, and gallstone pancreatitis. Clinical outcomes associated with disease presentation were analyzed. Statistical analysis was performed using the Student’s t-test, chi-square test, ANOVA, and logistic regression. RESULTS: There were 6,662 patients with SCD who presented with cholelithiasis. Median age was 20 (interquartile range 16 to 34) years and 54% were female patients. Cholecystectomy was performed in 1,779 patients with SCD with the most common indication being chronic cholecystitis (44%), followed by uncomplicated cholelithiasis (27%), acute cholecystitis (21%), and choledocholithiasis or gallstone pancreatitis (8%). On multivariable regression, advanced clinical presentation was the strongest predictor of perioperative vaso-occlusive crisis, which was the most common complication. Patients undergoing cholecystectomy for uncomplicated cholelithiasis were at lower risk than those with acute cholecystitis (odds ratio [OR] 2.37; 95% CI 1.64 to 3.41), chronic cholecystitis (OR 1.74; 95% CI 1.26 to 2.4), and choledocholithiasis or gallstone pancreatitis (OR 2.24; 95% CI 1.41 to 3.57). CONCLUSIONS: Seventy-three percent of patients with SCD have advanced clinical presentation at the time of their cholecystectomy. After cholecystectomy, perioperative vaso-occlusive events were significantly increased in patients with advanced clinical presentation. These data support screening abdominal ultrasounds and early cholecystectomy for cholelithiasis in patients with SCD.
Cholestatic Drug-Induced Liver Injury in a Patient Taking High-Dose Niacin for Hyperlipidemia
Nawaz, Nanjiba , Mistretta, Tyler, Karime, Christian , Wolf, Emily, Wolf, Emily B , Mistretta, Tyler , Lewis, Jason S.

Journal of Investigative Medicine High Impact Case Reports | January 9, 2024 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/23247096231224349 | PMID 38193433 Get It

Niacin, an important component of a balanced diet, is central to lipid metabolism. Occasionally used to treat hyperlipidemia, niacin is widely available without a prescription, making its use often unknown to treating physicians. Severe hepatotoxicity has been reported with niacin use. In the following report, we describe a case of hospitalization for acute decompensated cirrhosis with cholestatic morphology in a patient taking self-initiated large quantities of extended-release niacin. Despite medical management and support, the patient unfortunately expired on day 16 of hospitalization. Given ease of access and unclear long-term benefit in hyperlipidemia, the current case serves to raise awareness of niacin’s potential hepatotoxicity through highlighting a severe outcome. Although mode of liver injury remains unknown, the use of extended-release niacin formulations and prolonged high-dose supplementation is associated with enhanced hepatotoxicity. Careful review and counseling of commonly available supplements remains an important task of both hospital and primary care physicians.
Multi-Site Microbiome Composition in Atopic Dermatitis: A Case-Control Study
Pitlick, Mitchell M. , Johnson, Stephen , Mullakary, Roshini M. , Taneja, Veena , Joshi, Avni Y. , Taneja, Veena , Johnson, Stephen

Annals of Dermatology | January 9, 2024 | Volume: 36 | Issue: 1 | Pages: 55

10.5021/ad.22.117 | PMID 38325434 Get It

Temporal bone management in external and middle ear carcinoma
Gowrishankar, Shravan , Marinelli, John P. , Marinelli, John, Borsetto, Daniele , Panizza, Benedict James

Current Opinion in Otolaryngology & Head & Neck Surgery | January 9, 2024 | Volume: 32 | Issue: 2 | Pages: 138-142

10.1097/moo.0000000000000959 | PMID 38193562 Get It

Purpose of review The purpose of this review is to outline the temporal bone management of external and middle ear carcinoma. The review will outline the current evidence involved in deciding which surgical approach to take, as well as new advances in auditory rehabilitation and immunotherapy. Recent findings Traditional surgical approaches include lateral temporal bone resection, subtotal temporal bone resection and total temporal bone resection. They can also involve parotidectomy and neck dissection depending on extension of disease into these areas. Options for auditory rehabilitation include osseointegrated hearing aids, transcutaneous bone-conduction implants, and active middle ear implants. Recent advances in immunotherapy have included the use of anti-PD-1 monoclonal antibodies. Summary The mainstay of management of temporal bone disease involves surgical resection. Early-stage tumours classified according to the Pittsburgh staging tool can often be treated with lateral temporal bone resection, whereas late-stage tumours might need subtotal or total temporal bone resection. Parotidectomy and neck dissection might also be indicated if there is a risk of occult regional disease. Recent advances in immunotherapy have been promising, particularly around anti-PD-1 inhibitors. However, larger clinical trials will be required to test the extent of efficacy, particularly around combination use with surgery.
Neurosurgery for the rhinologist
Nizzola, Mariagrazia , Leonel, Luciano, Peris‐Celda, Maria

Current Opinion in Otolaryngology & Head & Neck Surgery | January 9, 2024 | Volume: 32 | Issue: 1 | Pages: 40-49

10.1097/moo.0000000000000950 | PMID 38193519 Get It

Purpose of review The purpose of this review is to provide a comprehensive anatomical appraisal of the neurosurgical anatomy exposed through the endonasal and paranasal sinuses routes, focusing on the most common expanded endonasal approaches (EEAs) as well as recent advances in this surgical field. Recent findings The EEAs are redefining the management of skull base pathology. Neurovascular structures previously considered a limitation, can be now approached through these surgical corridors. Advances in this field include the development of new surgical techniques and routes that allow better visualization and access to pathologies located in the ventral skull base. Understanding the surgical anatomy related to EEAs is essential not only for neurosurgeons but also for rhinologists. Summary Knowledge of the surgical anatomy of the most common EEAs that utilize paranasal sinuses as a surgical corridor enables more effective management of complex skull base pathologies. Comprehensive anatomical knowledge of these corridors and the surrounding neurovascular structures is crucial to maximize benefits of EEAs and improve outcomes.
Myosin Inhibitors Can Reduce Primary Mitral Regurgitation by Improving Systolic Anterior Motion of the Mitral Leaflets
Roehl, Kaitlin , Alsidawi, Said , Alsidawi, Said

Korean Circulation Journal | January 9, 2024 | Volume: 54 | Issue: 2 | Pages: 108

10.4070/kcj.2023.0290 | PMID 38346698 Get It

Whole‐exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways
White, Jason , Adeniji, Kayode , Jibrin, Paul, Obafunwa, John , Ogo, Chidiebere, Popoola, Ademola , Fatiregun, Omolara , Oluwole, Olabode P., Thorpe, Roland J. , Karanam, Balasubramanyam , Polak, Paz , Brignole, Kathryn R. , Dean‐Colomb, Windy, Odedina, Folake T., Yates, Clayton , White, Jason A , Popoola, Ademola A , Brignole, Kathryn R , Yates, Clayton , Fatiregun, Omolara , Kaninjing, Ernest , Faruk, Mohammed , Elhussin, Isra , Ambs, Stefan , Tang, Wei , Davis, Melissa , Campbell, Moray J. , Rotimi, Solomon O.

The Prostate | January 9, 2024 | Volume: 84 | Issue: 5 | Pages: 460-472

10.1002/pros.24662 | PMID 38192023 Get It

AbstractBackgroundThrough whole‐exome sequencing of 60 formalin‐fixed paraffin‐embedded Nigerian (NGRn) benign prostatic hyperplasia (BPH) samples, we identified germline and somatic alterations in apoptotic pathways impacting BPH development and progression. Prostate enlargement is a common occurrence in male aging; however, this enlargement can lead to lower urinary tract symptoms that negatively impact quality of life. This impact is disproportionately present in men of African ancestry. BPH pathophysiology is poorly understood and studies examining non‐European populations are lacking.MethodsIn this study, NGRn BPH, normal prostate, and prostate cancer (PCa) tumor samples were sequenced and compared to characterize genetic alterations in NGRn BPH.ResultsTwo hundred and two nonbenign, ClinVar‐annotated germline variants were present in NGRn BPH samples. Six genes [BRCA1 (92%), HSD3B1 (85%), TP53 (37%), PMS2 (23%), BARD1 (20%), and BRCA2 (17%)] were altered in at least 10% of samples; however, compared to NGRn normal and tumor, the frequency of alterations in BPH samples showed no significant differences at the gene or variant level. BRCA2_rs11571831 and TP53_rs1042522 germline alterations had a statistically significant co‐occurrence interaction in BPH samples. In at least two BPH samples, 173 genes harbored somatic variants known to be clinically actionable. Three genes (COL18A1, KIF16B, and LRP1) showed a statistically significant (p < 0.05) higher frequency in BPH. NGRn BPH also had five gene pairs (PKD1/KIAA0100, PKHD1/PKD1, DNAH9/LRP1B, NWD1/DCHS2, and TCERG1/LMTK2) with statistically significant co‐occurring interactions. Two hundred and seventy‐nine genes contained novel somatic variants in NGRn BPH. Three genes (CABP1, FKBP1C, and RP11‐595B24.2) had a statistically significant (p < 0.05) higher alteration frequency in NGRn BPH and three were significantly higher in NGRn tumor (CACNA1A, DMKN, and CACNA2D2). Pairwise Fisher's exact tests showed 14 gene pairs with statistically significant (p < 0.05) interactions and four interactions approaching significance (p < 0.10). Mutational patterns in NGRn BPH were similar to COSMIC (Catalog of Somatic Mutations in Cancer) signatures associated with aging and dysfunctional DNA damage repair.ConclusionsNGRn BPH contained significant germline alteration interactions (BRCA2_rs11571831 and TP53_rs1042522) and increased somatic alteration frequencies (LMTK2, LRP1, COL18A1, CABP1, and FKBP1C) that impact apoptosis. Normal prostate development is maintained by balancing apoptotic and proliferative activity. Dysfunction in either mechanism can lead to abnormal prostate growth. This work is the first to examine genomic sequencing in NGRn BPH and provides data that fill known gaps in the understanding BPH and how it impacts men of African ancestry.
When cystoscopy catches what laparoscopy misses: The role of cystoscopy in evaluation of bladder endometriosis
Ranieri, Gina , Yi, Johnny , Whitney, Madeline Ann, Whitney, Madeline , Wasson, Megan

Journal of Endometriosis and Pelvic Pain Disorders | January 9, 2024 | Volume: 16 | Issue: 1 | Pages: 66-68

10.1177/22840265231220731 Get It

Navigating Now and Next: Recent Advances and Future Horizons in Robotic Radical Prostatectomy
Mian, Abrar , Tollefson, Matthew K. , Shah, Paras , Sharma, Vidit , Mian, Ahmed, Mian, Ahmed, Thompson, R. Houston, Boorjian, Stephen A. , Frank, Igor, Khanna, Abhinav, Mian, Abrar H , Mian, Ahmed, Mian, Ahmed

Journal of Clinical Medicine | January 9, 2024 | Volume: 13 | Issue: 2 | Pages: 359

10.3390/jcm13020359 | PMID 38256493 Get It

Robotic-assisted radical prostatectomy (RARP) has become the leading approach for radical prostatectomy driven by innovations aimed at improving functional and oncological outcomes. The initial advancement in this field was transperitoneal multiport robotics, which has since undergone numerous technical modifications. These enhancements include the development of extraperitoneal, transperineal, and transvesical approaches to radical prostatectomy, greatly facilitated by the advent of the Single Port (SP) robot. This review offers a comprehensive analysis of these evolving techniques and their impact on RARP. Additionally, we explore the transformative role of artificial intelligence (AI) in digitizing robotic prostatectomy. AI advancements, particularly in automated surgical video analysis using computer vision technology, are unprecedented in their scope. These developments hold the potential to revolutionize surgeon feedback and assessment and transform surgical documentation, and they could lay the groundwork for real-time AI decision support during surgical procedures in the future. Furthermore, we discuss future robotic platforms and their potential to further enhance the field of RARP. Overall, the field of minimally invasive radical prostatectomy for prostate cancer has been an incubator of innovation over the last two decades. This review focuses on some recent developments in robotic prostatectomy, provides an overview of the next frontier in AI innovation during prostate cancer surgery, and highlights novel robotic platforms that may play an increasing role in prostate cancer surgery in the future.
Implicit Bias and Health Disparities Education in the Neonatal Intensive Care Unit
Dyess, Nicolle Fernández , Carr, Cara Beth , Mavis, Stephanie C. , Caruso, Catherine G. , Izatt, Susan , French, Heather , Bonachea, Elizabeth , Gray, Megan M , Dadiz, Rita

American Journal of Perinatology | January 9, 2024 | Volume: 41 | Issue: 12 | Pages: 1634-1644

10.1055/a-2240-1979 | PMID 38190976 Get It

Objective This study aimed to characterize implicit bias (IB) and health disparities (HD) education in neonatal–perinatal medicine (NPM), including current educational opportunities, resources, and barriers. Study Design A national web-based survey was sent to NPM fellows, neonatologists, and frontline providers after iterative review by education experts from the National Neonatology Curriculum Committee. Quantitative data were analyzed with chi-square and Fisher's exact tests. Qualitative data were evaluated using thematic analysis. Results Of the 452 NPM survey respondents, most desired additional IB (76%) and HD (83%) education. A greater proportion of neonatologists than fellows received IB (83 vs. 57%) and HD (87 vs. 74%) education. Only 41% of neonatologists reported that their institution requires IB training. A greater proportion of fellows than neonatologists expressed dissatisfaction with the current approaches for IB (51 vs. 25%, p < 0.001) and HD (43 vs. 25%, p = 0.015) education. The leading drivers of dissatisfaction included insufficient time spent on the topics, lack of specificity to NPM, inadequate curricular scope or depth, and lack of local educator expertise. A minority of faculty who were tasked to educate others have received specific educator training on IB (21%) and HD (16%). Thematic analysis of survey free-text responses identified three main themes on the facilitators and barriers to successful IB and HD education: individual, environmental, and curricular design variables. Conclusion NPM trainees and neonatologists desire tailored, active, and expert-guided IB and HD education. Identified barriers are important to address in developing an effective IB/HD curriculum for the NPM community. Key Points